Pharmacologic management of multiple sclerosis.
Blasier
Mary Gail
MG
Urology Department, Veterans' Administration Hospital, Ann Arbor, MI, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D019468:Disease Management; D018450:Disease Progression; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D000069442:Natalizumab; D010455:Peptides / Q000627:therapeutic use; D015985:Precipitating Factors; D011379:Prognosis; D011788:Quality of Life
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D008942:Mitoxantrone